An Overview of Influenza Viruses and Vaccines
Tóm tắt
Từ khóa
Tài liệu tham khảo
Klimov, 2012, WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011, Vaccine, 30, 6461, 10.1016/j.vaccine.2012.07.089
CDC (2020, January 22). Types of Influenza Viruses, Available online: https://www.cdc.gov/flu/about/viruses/types.htm.
Asha, K., and Kumar, B. (2019). Emerging Influenza D Virus Threat: What We Know So Far!. J. Clin. Med., 8.
Dawson, 2017, RNA structure interactions and ribonucleoprotein processes of the influenza A virus, Brief. Funct. Genom., 17, 402
Saunders-Hastings, P.R., and Krewski, D. (2016). Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission. Pathogens, 5.
Steel, 2013, Spherical influenza viruses have a fitness advantage in embryonated eggs, while filament-producing strains are selected in vivo, J. Virol., 87, 13343, 10.1128/JVI.02004-13
Gaymard, 2016, Functional balance between neuraminidase and haemagglutinin in influenza viruses, Clin. Microbiol. Infect., 22, 975, 10.1016/j.cmi.2016.07.007
Harris, 2006, Influenza virus pleiomorphy characterized by cryoelectron tomography, Proc. Natl. Acad. Sci. USA, 103, 19123, 10.1073/pnas.0607614103
Terrier, 2011, Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles, Virology, 414, 51, 10.1016/j.virol.2011.03.011
Tong, 2012, A distinct lineage of influenza A virus from bats, Proc. Natl. Acad. Sci. USA, 109, 4269, 10.1073/pnas.1116200109
De Vries, R.D., Herfst, S., and Richard, M. (2018). Avian Influenza A Virus Pandemic Preparedness and Vaccine Development. Vaccines, 6.
Asaduzzaman, 2015, The coexistence or replacement of two subtypes of influenza, Math. Biosci., 270, 1, 10.1016/j.mbs.2015.09.006
Petric, 2006, Role of the Laboratory in Diagnosis of Influenza during Seasonal Epidemics and Potential Pandemics, J. Infect. Dis., 194, S98, 10.1086/507554
Zebedee, 1988, Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions, J. Virol., 62, 2762, 10.1128/jvi.62.8.2762-2772.1988
Knipe, D.M., and Howley, P.M. (2007). Orthomyxoviridae: The viruses and their replication. Fields Virol, Lippincott Williams & Wilkins. [5th ed.].
Wolff, T., and Veit, M. (2021). Influenza B, C and D Viruses (Orthomyxoviridae). Encyclopedia of Virology, Academic Press.
Kuchipudi, S.V., Nelli, R.K., Gontu, A., Satyakumar, R., Surendran Nair, M., and Subbiah, M. (2021). Sialic Acid Receptors: The Key to Solving the Enigma of Zoonotic Virus Spillover. Viruses, 13.
Samji, 2009, Influenza A: Understanding the viral life cycle, Yale J. Biol. Med., 82, 153
Engelhardt, 2005, Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II, J. Virol., 79, 5812, 10.1128/JVI.79.9.5812-5818.2005
Nayak, 2009, Influenza virus morphogenesis and budding, Virus Res., 143, 147, 10.1016/j.virusres.2009.05.010
Gamblin, 2010, Influenza hemagglutinin and neuraminidase membrane glycoproteins, J. Biol. Chem., 285, 28403, 10.1074/jbc.R110.129809
Hai, 2012, Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes, J. Virol., 86, 5774, 10.1128/JVI.00137-12
Velkov, 2013, The antigenic architecture of the hemagglutinin of influenza H5N1 viruses, Mol. Immunol., 56, 705, 10.1016/j.molimm.2013.07.010
Wohlbold, 2014, In the shadow of hemagglutinin: A growing interest in influenza viral neuraminidase and its role as a vaccine antigen, Viruses, 6, 2465, 10.3390/v6062465
Thomson, 2009, Anti-influenza drugs: The development of sialidase inhibitors, Handb. Exp. Pharm., 189, 111, 10.1007/978-3-540-79086-0_5
Byrd-Leotis, L., Cummings, R.D., and Steinhauer, D.A. (2017). The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase. Int. J. Mol. Sci., 18.
York, 2019, Influenza virus N-linked glycosylation and innate immunity, Biosci. Rep., 39, BSR20171505, 10.1042/BSR20171505
Vigerust, 2007, Virus glycosylation: Role in virulence and immune interactions, Trends Microbiol., 15, 211, 10.1016/j.tim.2007.03.003
Kim, P., Jang, Y.H., Kwon, S.B., Lee, C.M., Han, G., and Seong, B.L. (2018). Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs. Viruses, 10.
Job, 2013, Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses, J. Immunol., 190, 2169, 10.4049/jimmunol.1202433
Wanzeck, 2011, Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice, Am. J. Respir. Crit. Care Med., 183, 767, 10.1164/rccm.201007-1184OC
Kobayashi, 2012, Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin, J. Virol., 86, 3446, 10.1128/JVI.06147-11
Cruz, 2018, Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry, Hum. Vaccines Immunother., 14, 508, 10.1080/21645515.2017.1377871
Fiore, 2010, Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Recomm. Rep., 59, 1
Barr, 2010, Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season, Vaccine, 28, 1156, 10.1016/j.vaccine.2009.11.043
Chang, 2019, Why Glycosylation Matters in Building a Better Flu Vaccine, Mol. Cell Proteom., 18, 2348, 10.1074/mcp.R119.001491
Saito, 1995, Steps in maturation of influenza A virus neuraminidase, J. Virol., 69, 5011, 10.1128/jvi.69.8.5011-5017.1995
Wang, 2008, The cotranslational maturation program for the type II membrane glycoprotein influenza neuraminidase, J. Biol. Chem., 283, 33826, 10.1074/jbc.M806897200
Bao, 2021, N-Linked Glycosylation Plays an Important Role in Budding of Neuraminidase Protein and Virulence of Influenza Viruses, J. Virol., 95, e02042-20, 10.1128/JVI.02042-20
Iuliano, 2018, Estimates of global seasonal influenza-associated respiratory mortality: A modelling study, Lancet, 391, 1285, 10.1016/S0140-6736(17)33293-2
WHO (2019, December 02). Influenza (Seasonal). Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
Fleming, 1999, The duration and magnitude of influenza epidemics: A study of surveillance data from sentinel general practices in England, Wales and the Netherlands, Eur. J. Epidemiol., 15, 467, 10.1023/A:1007525402861
Boni, 2008, Vaccination and antigenic drift in influenza, Vaccine, 26, C8, 10.1016/j.vaccine.2008.04.011
McCaughey, 2010, Influenza: A virus of our times, Ulst. Med. J., 79, 46
Potter, 2001, A history of influenza, J. Appl. Microbiol., 91, 572, 10.1046/j.1365-2672.2001.01492.x
Hampson, 2003, The epidemiology and clinical impact of pandemic influenza, Vaccine, 21, 1762, 10.1016/S0264-410X(03)00069-0
Scholtissek, 1978, On the origin of the human influenza virus subtypes H2N2 and H3N2, Virology, 87, 13, 10.1016/0042-6822(78)90153-8
Jester, 2019, Historical and clinical aspects of the 1918 H1N1 pandemic in the United States, Virology, 527, 32, 10.1016/j.virol.2018.10.019
Johnson, 2002, Updating the accounts: Global mortality of the 1918–1920 “Spanish” influenza pandemic, Bull. Hist. Med., 76, 105, 10.1353/bhm.2002.0022
Kayser, V., and Ramzan, I. (2021). Vaccines and Vaccination: History and Emerging Issues. Hum. Vaccines Immunother., 17.
Spreeuwenberg, 2018, Reassessing the Global Mortality Burden of the 1918 Influenza Pandemic, Am. J. Epidemiol., 187, 2561, 10.1093/aje/kwy191
Taubenberger, 2019, The 1918 influenza pandemic: 100 years of questions answered and unanswered, Sci. Transl. Med., 11, eaau5485, 10.1126/scitranslmed.aau5485
Viboud, 2016, Global Mortality Impact of the 1957-1959 Influenza Pandemic, J. Infect. Dis., 213, 738, 10.1093/infdis/jiv534
Oxford, 2000, Influenza A pandemics of the 20th century with special reference to 1918: Virology, pathology and epidemiology, Rev. Med. Virol., 10, 119, 10.1002/(SICI)1099-1654(200003/04)10:2<119::AID-RMV272>3.0.CO;2-O
CDC (2019, December 05). 1968 Pandemic (H3N2 Virus), Available online: https://www.cdc.gov/flu/pandemic-resources/1968-pandemic.html.
Mena, 2016, Origins of the 2009 H1N1 influenza pandemic in swine in Mexico, eLife, 5, e16777, 10.7554/eLife.16777
WHO (2020, November 29). What Is the Pandemic (H1N1) 2009 Virus?. Available online: https://www.who.int/csr/disease/swineflu/frequently_asked_questions/about_disease/en/.
Taubenberger, 2010, Influenza: The once and future pandemic, Public Health Rep., 125, 16, 10.1177/00333549101250S305
Peiris, 2004, Re-emergence of fatal human influenza A subtype H5N1 disease, Lancet, 363, 617, 10.1016/S0140-6736(04)15595-5
Chowdhury, S., Hossain, M.E., Ghosh, P.K., Ghosh, S., Hossain, M.B., Beard, C., Rahman, M., and Rahman, M.Z. (2019). The Pattern of Highly Pathogenic Avian Influenza H5N1 Outbreaks in South Asia. Trop. Med. Infect. Dis., 4.
WHO (2020, January 15). Influenza (Avian and Other Zoonotic). Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic).
CDC (2021, September 10). Highly Pathogenic Asian Avian Influenza A(H5N1) in People, Available online: https://www.cdc.gov/flu/avianflu/h5n1-people.htm.
WHO (2019, December 04). Avian Influenza Weekly Update Number 716. Available online: https://www.who.int/docs/default-source/wpro---documents/emergency/surveillance/avian-influenza/ai-20191122.pdf?sfvrsn=30d65594_42.
Young, 2018, Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies, J. Infect. Dis., 217, 731, 10.1093/infdis/jix632
Weir, 2016, An overview of the regulation of influenza vaccines in the United States, Influenza Other Respir. Viruses, 10, 354, 10.1111/irv.12383
Gutierrez, 2015, Recombinant hemagglutinin protein vaccine: A new option in immunization against influenza, Future Virol., 10, 1057, 10.2217/fvl.15.75
Yamayoshi, 2019, Current and future influenza vaccines, Nat. Med., 25, 212, 10.1038/s41591-018-0340-z
Xie, 2015, H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps, Sci. Rep., 5, 15279, 10.1038/srep15279
Statler, 2019, Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6–59 months of age: A phase 3, randomized, noninferiority study, Vaccine, 37, 343, 10.1016/j.vaccine.2018.07.036
McKeage, 2013, Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): A review of its use in the prevention of disease caused by influenza A and B, Drugs, 73, 1587, 10.1007/s40265-013-0114-3
Ray, 2016, Evidence update: GlaxoSmithKline’s inactivated quadrivalent influenza vaccines. Expert Rev, Vaccines, 15, 201
Robertson, 2016, Fluzone® High-Dose Influenza Vaccine. Expert Rev, Vaccines, 15, 1495
Suryadevara, 2014, Quadrivalent influenza vaccine in the United States. Hum, Vaccines Immunother., 10, 596, 10.4161/hv.27115
Sullivan, 2019, Heterogeneity in influenza seasonality and vaccine effectiveness in Australia, Chile, New Zealand and South Africa: Early estimates of the 2019 influenza season, Eurosurveillance, 24, 1900645, 10.2807/1560-7917.ES.2019.24.45.1900645
Montomoli, E., Torelli, A., Manini, I., and Gianchecchi, E. (2018). Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Vaccines, 6.
Zhao, 2019, Summary of the NACI Seasonal Influenza Vaccine Statement for 2019-2020, Can. Commun. Dis. Rep., 45, 149, 10.14745/ccdr.v45i06a01
Tsai, 2013, Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults, Infect. Chemother., 45, 159, 10.3947/ic.2013.45.2.159
Essink, 2020, Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults, Vaccine, 38, 242, 10.1016/j.vaccine.2019.10.021
Dunkle, 2015, Introducing Modern Recombinant Technology to the Realm of Seasonal Influenza Vaccine: Flublok® For Prevention of Influenza in Adults, EC Microbiol., 2, 224
Lamb, 2019, Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza, Drugs, 79, 1337, 10.1007/s40265-019-01176-z
Baxter, 2017, Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49years, Vaccine, 35, 1254, 10.1016/j.vaccine.2017.01.062
Hoft, 2017, Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults, Clin. Vaccine Immunol., 24, e00414-16, 10.1128/CVI.00414-16
Scheifele, 1991, Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel, CMAJ, 145, 213
Soema, 2015, Current and next generation influenza vaccines: Formulation and production strategies, Eur. J. Pharm. Biopharm., 94, 251, 10.1016/j.ejpb.2015.05.023
Sabbaghi, 2019, Inactivation methods for whole influenza vaccine production, Rev. Med. Virol., 29, e2074, 10.1002/rmv.2074
Lee, 2016, Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopy, Hum. Vaccines Immunother., 12, 1757
Squarcione, 2003, Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects, Vaccine, 21, 1268, 10.1016/S0264-410X(02)00401-2
Chua, 2019, Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement, Influenza Other Respir. Viruses, 14, 92
Maassab, 1967, Adaptation and growth characteristics of influenza virus at 25 degrees C, Nature, 213, 612, 10.1038/213612a0
Beyer, 2002, Cold-adapted live influenza vaccine versus inactivated vaccine: Systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: A meta-analysis, Vaccine, 20, 1340, 10.1016/S0264-410X(01)00471-6
Suzuki, 2015, Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus, Proc. Natl. Acad. Sci. USA, 112, 7809, 10.1073/pnas.1503885112
King, 2000, Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults, J. Infect. Dis., 181, 725, 10.1086/315246
Belshe, 1998, The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children, N. Engl. J. Med., 338, 1405, 10.1056/NEJM199805143382002
Keitel, 1994, Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans, J. Infect. Dis., 169, 477, 10.1093/infdis/169.2.477
Cox, 2009, FluBlok, a next generation influenza vaccine manufactured in insect cells, Biologicals, 37, 182, 10.1016/j.biologicals.2009.02.014
Geisler, 2018, Adventitious viruses in insect cell lines used for recombinant protein expression, Protein Expr. Purif., 144, 25, 10.1016/j.pep.2017.11.002
Grohskopf, 2018, Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018–2019 Influenza Season, MMWR Recomm Rep., 67, 1, 10.15585/mmwr.rr6703a1
Cox, 2008, FluBlok, a recombinant hemagglutinin influenza vaccine, Influenza Other Respir. Viruses, 2, 211, 10.1111/j.1750-2659.2008.00053.x
Treanor, 2001, Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans, Vaccine, 19, 1732, 10.1016/S0264-410X(00)00395-9
Wong, 2013, Traditional and new influenza vaccines, Clin. Microbiol. Rev., 26, 476, 10.1128/CMR.00097-12
DeMarcus, 2019, Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017–2018 influenza season, Vaccine, 37, 4015, 10.1016/j.vaccine.2019.06.004
Milian, 2015, Current and emerging cell culture manufacturing technologies for influenza vaccines, Biomed Res. Int., 2015, 504831, 10.1155/2015/504831
Rajao, 2018, Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture, Front. Microbiol., 9, 123, 10.3389/fmicb.2018.00123
CDC (2020, November 24). Cell-Based Flu Vaccines, Available online: https://www.cdc.gov/flu/protect/vaccine/cell-based.htm.
Couch, 2008, Seasonal inactivated influenza virus vaccines, Vaccine, 26, D5, 10.1016/j.vaccine.2008.05.076
Tate, 2014, Playing hide and seek: How glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection, Viruses, 6, 1294, 10.3390/v6031294
Krause, J.C., and Crowe, J.E. (2014). Committing the Oldest Sins in the Newest Kind of Ways-Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head. Microbiol. Spectr., 2.
Ping, 2015, Development of high-yield influenza A virus vaccine viruses, Nat. Commun., 6, 8148, 10.1038/ncomms9148
Stohr, 2012, Influenza virus surveillance, vaccine strain selection, and manufacture, Methods Mol. Biol., 865, 147, 10.1007/978-1-61779-621-0_9
Skowronski, D.M., Janjua, N.Z., De Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J.A., Fonseca, K., Winter, A.L., Gubbay, J.B., and Krajden, M. (2014). Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE, 9.
Mochalova, 2003, Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs, Virology, 313, 473, 10.1016/S0042-6822(03)00377-5
Zost, 2017, Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains, Proc. Natl. Acad. Sci. USA, 114, 12578, 10.1073/pnas.1712377114
Hegde, 2015, Cell culture-based influenza vaccines: A necessary and indispensable investment for the future, Hum. Vaccines Immunother., 11, 1223, 10.1080/21645515.2015.1016666
An, 2013, Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms, J. Proteome Res., 12, 3707, 10.1021/pr400329k
Hutter, 2013, Toward animal cell culture-based influenza vaccine design: Viral hemagglutinin N-glycosylation markedly impacts immunogenicity, J. Immunol., 190, 220, 10.4049/jimmunol.1201060
Paules, 2018, Chasing Seasonal Influenza—The Need for a Universal Influenza Vaccine, N. Engl. J. Med., 378, 7, 10.1056/NEJMp1714916
Lin, 2017, The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells, Influenza Other Respir. Viruses, 11, 263, 10.1111/irv.12447
Tregoning, 2018, Adjuvanted influenza vaccines, Hum. Vaccines Immunother., 14, 550, 10.1080/21645515.2017.1415684
Nakayama, 2011, [Influenza vaccine and adjuvant], Yakugaku Zasshi, 131, 1723, 10.1248/yakushi.131.1723
Pelliccia, 2016, Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months, Nat. Commun., 7, 13520, 10.1038/ncomms13520
Grgacic, 2006, Virus-like particles: Passport to immune recognition, Methods, 40, 60, 10.1016/j.ymeth.2006.07.018
Zhao, 2013, Virus-like particle-based human vaccines: Quality assessment based on structural and functional properties, Trends Biotechnol., 31, 654, 10.1016/j.tibtech.2013.09.002
Gao, 2013, Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge, Antivir. Res., 98, 4, 10.1016/j.antiviral.2013.01.010
Giurgea, L.T., Morens, D.M., Taubenberger, J.K., and Memoli, M.J. (2020). Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine. Vaccines, 8.
Kumar, 2018, Novel Platforms for the Development of a Universal Influenza Vaccine, Front. Immunol., 9, 600, 10.3389/fimmu.2018.00600
Low, 2014, Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers, Vaccine, 32, 5041, 10.1016/j.vaccine.2014.07.011
Pillet, S., Couillard, J., Trépanier, S., Poulin, J.-F., Yassine-Diab, B., Guy, B., Ward, B.J., and Landry, N. (2019). Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults. PLoS ONE, 14.
Ren, 2018, Intramuscular and intranasal immunization with an H7N9 influenza virus-like particle vaccine protects mice against lethal influenza virus challenge, Int. Immunopharmacol., 58, 109, 10.1016/j.intimp.2017.12.020
Ramirez, 2018, A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles, Vaccine, 36, 873, 10.1016/j.vaccine.2017.12.053
Luo, 2018, Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice, Sci. Rep., 8, 4577, 10.1038/s41598-018-22874-w
Isibasi, 2011, Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico, Vaccine, 29, 7826, 10.1016/j.vaccine.2011.07.099
Kang, H.-J., Chu, K.-B., Lee, D.-H., Lee, S.-H., Park, B.R., Kim, M.-C., Kang, S.-M., and Quan, F.-S. (2019). Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS ONE, 14.
Pillet, 2016, A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults, Clin. Immunol., 168, 72, 10.1016/j.clim.2016.03.008
Fonteneau, 2003, Activation of influenza virus-specific CD4+ and CD8+ T cells: A new role for plasmacytoid dendritic cells in adaptive immunity, Blood, 101, 3520, 10.1182/blood-2002-10-3063
Guay, 2007, Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells, J. Virol., 81, 9131, 10.1128/JVI.00647-07
Grodeland, G., Mjaaland, S., Tunheim, G., Fredriksen, A.B., and Bogen, B. (2013). The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS ONE, 8.
Muszkat, 2003, Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine, Vaccine, 21, 1180, 10.1016/S0264-410X(02)00481-4
Su, 2016, Induction of mucosal immunity through systemic immunization: Phantom or reality?, Hum. Vaccines Immunother., 12, 1070, 10.1080/21645515.2015.1114195
Gauthier, 2019, Nanoparticle-Based Vaccines against Respiratory Viruses, Front. Immunol., 10, 22, 10.3389/fimmu.2019.00022
Rioux, 2014, PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine, J. Nanobiotechnol., 12, 19, 10.1186/1477-3155-12-19
Hiremath, J., Kang, K.I., Xia, M., Elaish, M., Binjawadagi, B., Ouyang, K., Dhakal, S., Arcos, J., Torrelles, J.B., and Jiang, X. (2016). Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs. PLoS ONE, 11.
Karch, 2017, Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge, Nanomedicine, 13, 241, 10.1016/j.nano.2016.08.030
Kim, 2018, Influenza Virus: Dealing with a Drifting and Shifting Pathogen, Viral Immunol., 31, 174, 10.1089/vim.2017.0141
Ohmit, 2011, Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection, J. Infect. Dis., 204, 1879, 10.1093/infdis/jir661
Corti, 2011, A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins, Science, 333, 850, 10.1126/science.1205669
Nachbagauer, 2021, A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial, Nat. Med., 27, 106, 10.1038/s41591-020-1118-7
Sautto, 2020, A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin, J. Immunol., 204, 375, 10.4049/jimmunol.1900379
Liu, 2017, Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol, Medicine, 96, e6339, 10.1097/MD.0000000000006339
Atsmon, 2012, Safety and immunogenicity of multimeric-001—A novel universal influenza vaccine, J. Clin. Immunol., 32, 595, 10.1007/s10875-011-9632-5
Preiss, 2016, Vaccine provision: Delivering sustained & widespread use, Vaccine, 34, 6665, 10.1016/j.vaccine.2016.10.079
Dey, 2014, Physicochemical and functional characterization of vaccine antigens and adjuvants, Expert Rev. Vaccines, 13, 671, 10.1586/14760584.2014.907528
Kon, T.C., Onu, A., Berbecila, L., Lupulescu, E., Ghiorgisor, A., Kersten, G.F., Cui, Y.-Q., Amorij, J.-P., and Van der Pol, L. (2016). Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes. PLoS ONE, 11.
Pedersen, 2014, Hemagglutination-inhibition assay for influenza virus subtype identification and the detection and quantitation of serum antibodies to influenza virus, Methods Mol. Biol., 1161, 11, 10.1007/978-1-4939-0758-8_2
Kaufmann, L., Syedbasha, M., Vogt, D., Hollenstein, Y., Hartmann, J., Linnik, J.E., and Egli, A. (2017). An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers. J. Vis. Exp., 55833.
Defang, G.N., Martin, N.J., Burgess, T.H., Millar, E.V., Pecenka, L.A., Danko, J.R., Arnold, J.C., Kochel, T.J., and Luke, T.C. (2012). Comparative Analysis of Hemagglutination Inhibition Titers Generated Using Temporally Matched Serum and Plasma Samples. PLoS ONE, 7.
Wood, 2018, Standardisation of inactivated influenza vaccines-Learning from history, Influenza Other Respir. Viruses, 12, 195, 10.1111/irv.12543
Engelhardt, 2018, Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen, Vaccine, 36, 4339, 10.1016/j.vaccine.2018.05.076
Cole, 2008, Analytical ultracentrifugation: Sedimentation velocity and sedimentation equilibrium, Methods Cell Biol., 84, 143, 10.1016/S0091-679X(07)84006-4
Weigel, 2019, Hydrophobic-interaction chromatography for purification of influenza A and B virus. J. Chromatogr. B Anal. Technol. Biomed, Life Sci., 1117, 103
Shytuhina, 2014, Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine, J. Chromatogr. A, 1364, 192, 10.1016/j.chroma.2014.05.087
Rustandi, 2016, Ion-Exchange Chromatography to Analyze Components of a Clostridium difficile Vaccine, Methods Mol. Biol., 1476, 269, 10.1007/978-1-4939-6361-4_20
Lancaster, 2016, A Size-Exclusion Chromatography Method for Analysis of Clostridium difficile Vaccine Toxins, Methods Mol. Biol., 1476, 279, 10.1007/978-1-4939-6361-4_21
Zhao, 2019, Affinity chromatography for vaccines manufacturing: Finally ready for prime time?, Vaccine, 37, 5491, 10.1016/j.vaccine.2018.02.090
Vajda, 2016, Size distribution analysis of influenza virus particles using size exclusion chromatography, J. Chromatogr. A, 1465, 117, 10.1016/j.chroma.2016.08.056
Tay, 2015, Investigation into alternative testing methodologies for characterization of influenza virus vaccine, Hum. Vaccines Immunother., 11, 1673, 10.1080/21645515.2015.1034914
Sahin, 2019, Preparation-free method can enable rapid surfactant screening during industrial processing of influenza vaccines, Vaccine, 37, 1073, 10.1016/j.vaccine.2018.12.069
Sahin, 2017, Nile Red fluorescence spectrum decomposition enables rapid screening of large protein aggregates in complex biopharmaceutical formulations like influenza vaccines, Vaccine, 35, 3026, 10.1016/j.vaccine.2017.04.066
Downard, 2009, Mass spectrometry analysis of the influenza virus, Mass Spectrom. Rev., 28, 35, 10.1002/mas.20194
Frahm, G.E., Pochopsky, A.W.T., Clarke, T.M., and Johnston, M.J.W. (2016). Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. PLoS ONE, 11.
Rhodes, 2009, Determination of size, molecular weight, and presence of subunits, Methods Enzym., 463, 691, 10.1016/S0076-6879(09)63039-1
Liu, 2006, A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation, AAPS J., 8, E580, 10.1208/aapsj080367
Baldwin, 2001, Matrix-assisted laser desorption/ionization coupled with quadrupole/orthogonal acceleration time-of-flight mass spectrometry for protein discovery, identification, and structural analysis, Anal. Chem., 73, 1707, 10.1021/ac0011080
Tarasov, M., Shanko, A., Kordyukova, L., and Katlinski, A. (2020). Characterization of Inactivated Influenza Vaccines Used in the Russian National Immunization Program. Vaccines, 8.
Filipe, 2013, Analytical approaches to assess the degradation of therapeutic proteins, TrAC Trends Anal. Chem., 49, 118, 10.1016/j.trac.2013.05.005
Lewnard, J.A., and Cobey, S. (2018). Immune History and Influenza Vaccine Effectiveness. Vaccines, 6.
CDC (2021, September 12). CDC Seasonal Flu Vaccine Effectiveness Studies, Available online: https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm.
Sullivan, S.G., Price, O.H., and Regan, A.K. (2019). Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations. Ther. Adv. Vaccines Immunother., 7.
Dhakal, 2019, Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs, J. Virol., 93, e00797-19, 10.1128/JVI.00797-19
DiazGranados, 2014, Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults, N. Engl. J. Med., 371, 635, 10.1056/NEJMoa1315727